行情

ADAP

ADAP

Adaptimmune治疗
NASDAQ

实时行情|Nasdaq Last Sale

7.98
-0.08
-0.99%
盘后: 7.98 0 0.00% 16:58 08/07 EDT
开盘
8.06
昨收
8.06
最高
8.18
最低
7.87
成交量
87.55万
成交额
--
52周最高
13.40
52周最低
0.7090
市值
12.02亿
市盈率(TTM)
-6.2677
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ADAP价格均价为12.67,最高价位17.00,最低价为9.00。

EPS

ADAP 新闻

更多
Adaptimmune EPS beats by $0.20, misses on revenue
Adaptimmune (NASDAQ:ADAP): Q2 GAAP EPS of -$0.04 beats by $0.20. Revenue of $0.5M (+212.5% Y/Y) misses by $0.43M. Shares +1.15% PM. Press Release
seekingalpha · 2天前
Adaptimmune Reports Q2 Financial Results and Business Update
\- Reported responses in multiple solid tumor types during ASCO with updates at upcoming congresses in Q4 -\- Continued progress toward launch of ADP-A2M4 for sarcoma in the US in 2022 with ongoing enrollment of patients in SPEARHEAD-1 - \- Granted access to
GlobeNewswire · 2天前
Adaptimmune Therapeutics shares are trading higher after the company late Thursday reported it was granted access to priority medicines regulatory support by EMA for ADP-A2M4 for treatment of Synovial Sarcoma. UPDATE: Shares have since reversed.
Benzinga · 07/24 14:01
Adaptimmune Therapeutics shares are trading higher after the company reported it was granted access to priority medicines regulatory support by EMA for ADP-A2M4 for treatment of Synovial Sarcoma.
Benzinga · 07/23 20:12
Adaptimmune's ADP-A2M4 nabs accelerated review in EU for soft tissue cancer
Seeking Alpha - Article · 07/23 20:10
Adaptimmune Therapeutics reports Was Granted Access To PRIority MEdicines Regulatory Support By EMA For ADP-A2M4 For Treatment Of Synovial Sarcoma
Benzinga · 07/23 20:00
Adaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial Sarcoma
PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 23, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the European Medicines Agency (EMA) has granted access to the PRIME initiative
GlobeNewswire · 07/23 20:00
Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020
PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for Q2 2020, before the U.S. marke
GlobeNewswire · 07/22 12:00

所属板块

生物技术和医学研究
-0.18%
制药与医学研究
+0.08%

热门股票

代码
价格
涨跌幅

ADAP 简况

Adaptimmune Therapeutics plc是一家临床阶段的生物制药公司。该公司致力于基于其T细胞受体(TCR)平台的癌症免疫治疗产品的开发。该公司已开发一个平台,能够识别多肽形态的癌症靶标(即氨基酸短序列),发现与基因制造TCR,并生产作为患者药物投放的TCR治疗候选产品。该公司对TCR进行基因改造,以增加其对癌症特异性多肽(包括先导目标多肽NY-ESO-1和MAGE-A10)的亲和力,已达到靶向患者癌细胞并将其消灭的目的。该公司的TCR治疗候选物能够靶向细胞内及细胞外癌抗原。TCR由两条关联的蛋白质链α链和β链组成,每条链有两个区域:可变区和恒定区。
展开

微牛提供Adaptimmune Therapeutics PLC - ADR(NASDAQ-ADAP)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ADAP股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ADAP股票基本功能。